Figures
- Figure 1.
Proportion of participants with access to a, b) a radiologist and c, d) a pathologist experienced in interstitial lung diseases to discuss cases of suspected idiopathic pulmonary fibrosis (IPF) in the a, c) 2013 Advancing IPF Research (AIR) survey and b, d) 2012 French survey. In total, there were 147 respondents.
- Figure 2.
Involvement of a multidisciplinary team in diagnosis in a) the 2013 Advancing IPF Research (AIR) survey and b) the 2012 French survey. In total, there were 146 respondents in each survey.
- Figure 3.
Average duration of symptoms before a diagnosis of idiopathic pulmonary fibrosis (IPF) is confirmed in the 2013 Advancing IPF Research survey. In total, there were 144 respondents.
- Figure 4.
Initial symptoms revealing the diagnosis of idiopathic pulmonary fibrosis (IPF) in the 2013 Advancing IPF Research survey and the proportion of physicians who made a diagnosis of IPF in patients referred/who sought medical advice for each of the symptoms. In total, there were 145 respondents. CT: computed tomography.
- Figure 5.
Percentage of physicians who prescribed each of the specified treatments in patients diagnosed with definite idiopathic pulmonary fibrosis (IPF) in the 2013 Advancing IPF Research survey. In total, there were 145 respondents. NAC: N-acetylcysteine.
- Figure 6.
Comorbidities/associated conditions/complications assessed in patients diagnosed with idiopathic pulmonary fibrosis (IPF) in the 2013 Advancing IPF Research survey. In total, there were 143 respondents. GORD: gastro-oesophageal reflux disease; PH: pulmonary hypertension; CV: cardiovascular.
